|
|
|
| home > white papers > R&D to Product: How to Reduce Costly Scale-Up Problems - Natoli Engineering Company, Inc. |
|
|
 WHITE PAPERS |
|
Natoli Engineering Company, Inc.
|
|
R&D to Product: How to Reduce Costly Scale-Up Problems
|
|
When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment
3P and Zhittya began their relationship at the beginning of 2019
with 3P being selected as the CDMO to transfer the process for scaling
up and performing cGMP manufacturing for clinical studies. After
successfully achieving transfer of the process, 3P anticipates
manufacturing of the first cGMP batch by the second quarter of 2020.
More info >> |
|
 |
White Papers |
 |
|
Quality By Design
Biopharma Group
Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Europe
18-21 October 2020, Barcelona, Spain
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >> |
|
|
|
.jpg)
